Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | SUV39H2 | Q9H5I1 | 3/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355729 | 0.85 | POLB (0.47) | NPY2RPOLBSCD5GPR119HDAC4 | |
| SCHEMBL355620 | 0.85 | POLB (0.45) | NPY2RPOLBSCD5GPR119HDAC4 | |
| SCHEMBL354726 | 0.75 | GPR119 (0.56) | NPY2RSCD5GPR119HDAC4TBK1 | |
| SCHEMBL4513470 | 0.74 | GPR119 (0.48) | GPR119 | |
| SCHEMBL355103 | 0.74 | GPR119 (0.54) | NPY2RGPR119HDAC4TBK1IKBKE | |
| SCHEMBL357253 | 0.74 | NPY2R (0.81) | NPY2R | |
| SCHEMBL354865 | 0.74 | GPR119 (0.55) | NPY2RSCD5GPR119HDAC4TBK1 | |
| SCHEMBL23533044 | 0.73 | MAPT (0.49) | GPR119SUV39H2BACE1 | |
| SCHEMBL16166510 | 0.73 | NR1H2 (0.51) | GPR119SUV39H2PIK3CABACE1 | |
| SCHEMBL28696198 | 0.71 | GPR119 (0.52) | POLBGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015957-A1 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY1R, NPY5R | NPY2R 1/4885POLB 4536/4885SCD5 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.